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Abstract
Hepatitis C virus infection is a frequent clinical problem in patients on dialysis and renal transplant
recipients. The local prevalence rates of hepatitis C virus infection in patients on peritoneal dialysis,
hemodialysis, or after kidney transplantation are 2%, 9%, and 6%, respectively. Conventional
diagnosis of hepatitis C virus infection is by anti-hepatitis C virus immunoassays. However, up to
10% of immunosuppressed patients may be negative for anti-hepatitis C virus but positive for
hepatitis C virus RNA. Repeated blood transfusions and a long duration of dialysis are major risk
factors for hepatitis C virus infection among patients with renal failure. Although the risk of acquiring
hepatitis C virus infection through transfusions has decreased considerably with the advent of
screening tests for anti-hepatitis C virus, precautionary measures should be instituted rigorously
at renal units to prevent nosocomial transmission. Hepatitis C virus infection in dialysis patients
often assumes a relatively mild course. In contrast, renal allograft recipients can develop potentially
life-threatening exacerbations, as exemplified by fibrosing cholestatic hepatitis. Liver disease of
variable severity can be observed in about two thirds of hepatitis C virus-positive renal allograft
recipients. In the majority of patients, however, the adverse effect of hepatitis C virus infection on
survival may not be evident in the first decade after renal transplantation. Hepatitis C virus-positive
patients with renal failure should not be excluded from kidney transplantation, but should be
assessed individually with regard to the severity of liver disease before transplantation. Dialysis
patients with hepatitis C virus infection, especially those with a potential for kidney transplantation,
should be considered for treatment with interferon, because the risk of interferon in inducing renal
allograft dysfunction is too high to justify its routine use in renal allograft recipients.
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EPIDEMIOLOGY, RISK FACTORS,
AND PREVENTION OF HEPATITIS
C VIRUS INFECTION
Both the incidence and prevalence of HCV infection are
increased in patients on renal replacement therapy
compared with the general population. The prevalence
of HCV infection demonstrates marked geographical
variation (Table 1). The risk is highest among patients
on hemodialysis, attributable to the higher transfusion
requirement before the availability of erythropoietin and
the increased risk of parenteral exposure to HCV.
Although transplantation of HCV-positive organs can
transmit infection, this risk has become minimal since
the screening of the donor HCV status, and most of the
HCV-infected renal transplant recipients have acquired
the infection during dialysis.
Risk factors for hepatitis C virus
infection in patients on dialysis
Among the risk factors for HCV infection in patients on
renal replacement therapy, the most important are a high
transfusion requirement before the introduction of blood
product screening for anti-HCV, a history of hemo-
dialysis, the duration of dialysis, and the prevalence of HCV
infection within a patient’s hemodialysis unit (Table 2). The
lower risk of HCV infection among peritoneal dialysis
patients has been attributed to their lower transfusion
requirement, reduced chance of parenteral exposure, and
fewer opportunities for nosocomial transmission. Indeed,
the relationship between the risk for HCV infection and
the prevalence within individual hemodialysis units
implies a genuine risk of cross-infection, which has been
corroborated by genetic identification of the specific HCV
strains involved (17,18).
INTRODUCTION
Liver disease due to infection by the hepatitis C virus
(HCV) or the hepatitis B virus (HBV) has an important
impact on the outcome of patients on renal replacement
therapy, and accounts for up to 30% of mortality in long-
term renal allograft recipients (1-3). The hepatitis C virus
was cloned in 1989, and has been identified as the major
cause of non-A non-B hepatitis (4,5). The problem of
HCV infection has continued to escalate because of the
lack of an effective vaccine.
Patients on long-term dialysis and renal allograft
recipients have increased risk of HCV infection,
consequent to their transfusion requirement and the
repeated risks of parenteral exposure in the former group,
as well as the possibility of transmission via the trans-
planted organ. In addition, the course of HCV-related liver
disease might exacerbate upon immunosuppression.
This article will review the current knowledge on the
incidence and prevalence, the diagnostic approach, the
major risk factors, and the measures to prevent HCV
infection in patients with end-stage renal failure. The
clinicopathological features of HCV-related liver disease
in dialysis patients and those after renal transplantation
will be discussed, although the impact of HCV infection
on the long-term outcome of renal allograft recipients
remains to be elucidated. Despite the improved efficacy
of treatment for HCV infection with pegylated interferon
with or without ribavirin in non-immunosuppressed
individuals, these results may not be extrapolated to
dialysis patients or those who have undergone kidney
transplantation, in view of differences in tolerability to
these therapeutic agents.
Table 1. Prevalence of HCV infection in patients on renal replacement therapy.
Anti-HCV+, % HCV RNA+, % Year/location Reference
Hemodialysis patients 16 1991/Hong Kong (6)
22 17 1993/Hong Kong (7)
19 1997/Spain (8)
27 23 1998/Miami, FL, US (9)
9 2001/Hong Kong (10)
Peritoneal dialysis patients 2 1991/Hong Kong (6)
6 1992/Taiwan (11)
7 1995/Singapore (12)
11 1996/Spain (13)
2 2001/Hong Kong (10)
Renal allograft recipients 10 12 1993/Hong Kong (14)
6 2001/Hng Kong (10)
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The incidence of new HCV infection has declined since
the late 1980s due to the increasing use of erythropoietin
and the screening of blood products and patients for HCV
status (19). However, we have recently observed a
disproportionately high incidence of new HCV infection
among patients who have received kidney allografts from
a neighboring region(s), especially in patients who have
undergone hemodialysis or have received blood
transfusions in these regions before transplantation.
These observations strongly suggested suboptimal
precautionary measures and/or screening of blood
products at the respective renal units.
Prevention of hepatitis C virus infection
in dialysis units
In view of the strong evidence for nosocomial trans-
mission, universal precautions and procedures specific
to hemodialysis units are crucial to minimize the risk of
infection. These include:
1. wearing or changing gloves and aprons before contact,
and washing hands after contact with patients, dialysis
equipment, or potentially infectious surfaces or
materials;
2. wearing a goggle or face mask and apron when
exposure to blood or body fluids is expected;
3. routine cleaning and disinfection procedures–the
dialysis circuit should be disinfected by standard
procedures, and the surfaces of dialysis machines
should be cleaned with an appropriate agent(s) after
each session;
4. prohibition of sharing instruments or medications
among patients, including multiuse vials; preparing
and distributing medications from a centralized area,
and avoiding the use of medication supply carts from
patient to patient.
The renal unit should have an established program for
regular surveillance of blood-borne viral infections in
dialysis patients. In the event of new HCV infections,
other susceptible patients who have shared the same
dialysis sessions and/or machines with the index patient
should be tested for HCV infection. Testing in high-risk
susceptible individuals should be performed weekly for
3 months. Susceptible patients who have returned to the
renal unit after receiving hemodialysis or a blood product
transfusion in high- or unknown-risk areas should be
tested for HCV infection covering the window period
and, before the results are known, managed as potentially
infected with the use of dedicated hemodialysis machines
until the risk is discounted.
Hepatitis C virus carriers should receive hemodialysis
using dedicated machines (20,21). Although the benefit
of segregating hemodialysis rooms has remained doubtful
provided that other precautionary measures are strictly
maintained, it is still advisable, particularly in units with
a high prevalence of HCV infection. Although the re-use
of hemodialyzers has not been associated with an
increased risk of viral hepatitis in patients or staff, it is
common practice to exclude dialyzers from HCV-positive
patients from re-use programs. Similarly, in view of the
detection of HCV in peritoneal dialysis effluent, this
should be handled as potentially infectious material (22).
Transmission of hepatitis C virus
through organ transplantation
Data from the New England Organ Bank studies (23,24)
have shown that about half of the recipients of organs
from HCV-positive donors acquired the infection, and
that life-threatening acute or chronic liver diseases could
develop. Other investigators have reported variable rates
of infection or the development of clinical manifestations
(25-27). As in renal allograft recipients with a pre-
existing HCV infection, it is difficult to predict the
clinical outcome in individual patients who acquire de
novo HCV infection after organ transplantation.
Nevertheless, it is imperative that HCV-positive organs
should not be transplanted into HCV-negative recipients.
However, data to date suggest that the transplantation of
HCV-positive kidneys into recipients who have a pre-
existing HCV infection may not have a detrimental effect
on the clinical outcome of the recipients up to 5 years
after transplantation (28). The clinical consequence of
superinfection with different genotypes of HCV remains
to be established.
DIAGNOSIS
Hepatitis C virus is a single-stranded linear RNA virus
from the Flaviviridae family. It has a lipid envelope, and
the genome contains approximately 9400 nucleotides.
Six major genotypes and more than 50 subtypes of HCV
have been identified to date, some of which have been
reported to be related to the clinical course and the
response to therapeutic interventions. The virus also
shows marked genetic heterogeneity, especially in the
amino terminal end of the hypervariable region 1, and
this has significant implications on serological diagnosis
and the development of vaccines (29,30).
Table 2. Factors affecting the risk of HCV infection in patients on
renal replacement therapy.
Factor Risk of HCV infection Reference
Blood transfusion  (6,15)
Duration of dialysis  (15)
Hemodialysis  (6,11)
Peritoneal dialysis  (6,8)
High prevalence of HCV  (16)
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Antibodies to hepatitis C virus
Testing for circulating non-neutralizing antibodies to
HCV (anti-HCV) is commonly used for the diagnosis of
HCV infection. The viral genome encodes, from the N-
terminal, the basic nucleocapsid (C), the first envelope
glycoprotein (E1), the second envelope/nonstructural-1
glycoprotein (E2/NS1), followed by the other non-
structural regions NS2, NS3, NS4, and NS5 (31).
Different generations of enzyme-linked immunosorbent
assays and recombinant immunoblot assays (RIBA) have
evolved for the detection of antibodies to different
components of HCV. Enzyme-linked immunosorbent
assays are more often used to screen a large number of
samples, whereas RIBA can be used for confirmation in
view of its higher specificity. First-generation im-
munoassays, which detect antibodies directed toward a
recombinant NS4 antigen c100, are associated with high
false-positive and -negative rates, and have become
obsolete. Second-generation anti-HCV assays, which
detect antibodies directed toward the c22 antigen from
the nucleocapsid and the c200 antigen from the NS3/NS4
regions (as well as the 5-1-1 antigen in RIBA2 assays),
have improved sensitivity and specificity, both of which
approach 95%, and they detect anti-HCV at 4 weeks after
exposure, compared with the 16-week window period for
the first-generation tests (32). An additional recombinant
antigen from the NS5 region is incorporated in third-
generation tests, which have sensitivity and specificity
rates of 97% and 100%, respectively (9,33).
Hepatitis C virus RNA
Hepatitis C virus RNA in blood samples can be detected
qualitatively by reverse transcription and polymerase
chain reaction (RT-PCR), using primers directed toward
the highly conserved 5' end of the viral genome (34).
The presence of circulating HCV RNA provides the
earliest evidence for HCV infection, often within 2 weeks
of infection. The test is highly sensitive, and can detect
HCV RNA at concentrations down to 2000 copies/mL.
In view of the technical complexity, the requirement for
careful handling of specimens, and the protocol variations
among different laboratories, this test is usually reserved
for confirmation of HCV infection status or for research
purposes, but not for routine clinical diagnoses.
Nevertheless, testing for HCV RNA is particularly useful
in patients who have tested negative for anti-HCV when
there is a high degree of suspicion based on clinical
manifestations. In this regard, 10% to 20% of dialysis or
transplant patients with HCV infection may be negative
for anti-HCV by second-generation immunoassays (32,
35-39). Furthermore, the presence of anti-HCV may not
indicate persistent infection in patients who have been
treated with interferon, where testing for HCV RNA is
required to indicate success or failure of treatment.
With regard to quantitative assays for HCV RNA,
quantitative PCR requires considerable technical
expertise, whereas the branched-chain DNA assay shows
better standardization and reproducibility. In this assay,
the HCV RNA is captured to a solid phase by probes to
the 5' untranslated and core regions, after which the signal
is amplified with the use of amplification multimers (40).
The test is less sensitive than RT-PCR, and detects HCV
RNA at concentrations down to 350 000 copies/mL.
Nevertheless, the procedure is automated and re-
producible, and provides useful information in patients
under treatment. In this context, studies with quantitative
assays have demonstrated that circulating levels of HCV
RNA were higher in patients with end-stage renal failure
compared with non-uremic patients (41).
Hepatitis C virus genotypes
In contrast to the 5' non-coding region, the E1 and E2/
NS1 regions of the HCV genome demonstrate much
genetic heterogeneity. Convention classification divides
HCV first into six major types, then into subtypes and
isolates (42). Sequence analysis, PCR with genotype
specific primers, restriction fragment length poly-
morphism analysis, and commercial line probe assays
can be used for the typing of HCV at corresponding levels
of precision (43-45). Infection with the 1b genotype has
been associated with more severe liver disease and a less
favorable response to interferon therapy, although the
pathogenetic role of genetic heterogeneity in HCV-
related liver disease remains to be defined (46-50). Our
previous study (51) showed that the common genotypes
in local patients on renal replacement therapy were 1b
(78%), 1a (10%), and 6a (8%).
CLINICAL MANIFESTATIONS
Hepatitis C virus infection can lead to acute or chronic
hepatitis. Acute hepatitis C is often asymptomatic or
associated with mild clinical manifestations. The
incubation period ranges from 1 to 26 weeks. Jaundice
is uncommon, and it is rare for patients to have signific-
ant impairment of liver function (52). In view of the
relatively minor clinical manifestations, regular
surveillance of HCV infection in high-risk groups is
indicated. It is to be noted that the development of anti-
HCV may be delayed, and testing for circulating HCV
RNA may be required for early diagnosis (53).
Hepatitis C virus infection is characterized by the
propensity for chronicity, which has been reported to
affect more than 80% of patients (54). The infection can
persist despite normalization of elevated transaminase
levels. Genetic heterogeneity and rapid mutation are
important factors contributing to the persistence of HCV
infection (55,56). Progression of liver disease in non-
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immunosuppressed individuals with chronic hepatitis C
is usually slow, with 20% to 50% of patients eventually
developing cirrhosis after 20 to 30 years (57,58).
Nevertheless, with the reduced incidence of HBV
infection after the introduction of vaccination programs,
chronic HCV infection has assumed increasing
importance as a major cause of chronic liver disease. In
this regard, more than 10 000 deaths in the United States
are attributable to HCV infection annually. It has been
reported that, annually, 1% to 2% of patients with
compensated cirrhosis caused by HCV experience
hepatocellular carcinoma (59,60), whereas 5- and 10-
year survival rates have been reported as 91% and 79%,
respectively, in non-immunosuppressed individuals (59).
Disease progression can be affected by multiple host or
viral factors (Table 3). It is interesting to note that the
load of viral inoculum does not seem to have an effect
on disease progression (67). In addition, the course of
HCV-related liver disease can be modulated by the
immune responsiveness of the host, so that accelerated
disease progression can occur in immunosuppressed
patients, as exemplified by fibrosing cholestatic hepatitis
(68).
Patients on dialysis and kidney
transplant recipients
Although the level of transaminases is related to the
activity of HCV-induced liver disease in general, the
correlation between biochemical and histological
manifestations is weak in individual patients. The normal
range of serum transaminases for patients without liver
disease is lower for dialysis patients compared with non-
dialyzed patients. An abnormal level of transaminases
has been noted in a variable proportion of HCV-positive
dialysis patients, ranging from less than 10% to 70%,
and is not a reliable indicator of the severity of liver
disease (7,69-71). Data from histological investigations
showed that the pathology of HCV-induced liver disease
in most patients on dialysis was relatively mild, and
similar to non-renal failure patients with persistently
normal transaminase levels (41).
We have reported that the level of circulating HCV RNA
increased upon immunosuppression (72). Although there
is a general trend that HCV-related liver disease also
becomes more severe after kidney transplantation, the
relationship between increased viral replication and
disease progression is again not absolute (73-75). A small
proportion of patients can develop fulminant exacer-
bation of HCV-induced liver disease, as exemplified by
fibrosing cholestatic hepatitis, whereas others can retain
apparent clinical stability over an extended period,
even without elevation in the level of liver enzymes
(68,76,77). Genotypic variations cannot totally account
for the heterogeneity in clinical manifestations (78). Our
previous study in local patients (14) showed that 70% of
HCV-positive renal allograft recipients developed
abnormal levels of liver enzymes, and 50% demonstrated
recurrent or persistent abnormalities. In addition to
elevated serum transaminase levels, these patients can
have prominent increases of the ductal enzymes. Half of
the patients showed histological evidence of chronic
hepatitis with variable degrees of cirrhosis, and histo-
logical abnormalities were more severe in patients with
persistent biochemical derangements. Our results also
showed that early onset of biochemical derangements
after kidney transplantation was associated with an
unfavorable liver prognosis (14).
Fibrosing cholestatic hepatitis can complicate HBV or
HCV infection in immunosuppressed patients, and is
characterized by periportal fibrosis, ballooning of
hepatocytes, marked cholestasis, yet relatively mild
inflammatory infiltration on histological examination,
in the face of markedly accelerated viral replication so
that the hepatocytes contain abundant virus particles (76).
This complication has been associated with a high
mortality, but can respond favorably to interferon therapy
(79). The pathogenesis is related to the suppressed host
immune responsiveness, thereby resulting in unabated
Table 3. Factors that may modulate the rate of progression or the severity of HCV-related liver disease.
Factor Effect Reference
Genetic polymorphisms with TGF β1 and angiotensin II  hepatic fibrosis (61)
Age of patient
  40-55 years  progression (57,62)
  Children  progression
Geographic locality   Different incidences of liver cancer (63)
Host immune response   Varied severity of chronic hepatitis (64)
Alcohol intake  progression (65)
HCV genotype   Varied severity (48-50)
Coinfection with HBV  severity (66)
Histologic inflammation and bridging fibrosis  progression (58)
TGF = transforming growth factor
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viral replication. With regard to the immunopathogenetic
mechanisms of HCV-induced liver disease in kidney
transplant recipients, we reported that peripheral blood
suppressor/cytotoxic T lymphocytes were increased,
whereas activated helper/inducer T lymphocytes and
natural killer cells were reduced in HCV-positive renal
allograft recipients (80). Furthermore, increased non-
major histocompatibility complex-restricted cytotoxic T
cells and reduced natural killer cells were associated with
the presence or absence of liver disease, respectively,
suggesting that immune mechanisms were involved in
the pathogenesis of chronic hepatitis C after renal
transplantation.
In view of the slow disease progression in the majority
of patients, long-term studies are required to examine
the impact of HCV infection on the morbidity and
mortality of kidney transplant recipients. In the majority
of renal allograft recipients, HCV infection per se does
not seem to reduce patient survival up to 7 years after
transplantation (69,73,78,81-83). Increased morbidity
and mortality attributable to liver disease have been
reported, especially in series with prolonged follow-up,
and it is likely that a significant proportion of patients
will ultimately experience liver complications (84,85).
Assessment of hepatitis C virus-positive
dialysis patients before kidney
transplantation
Although the risk of developing liver-related com-
plications is likely to increase with increasing time after
transplantation in HCV-positive renal allograft recipients,
the magnitude of such long-term risks may still compare
favorably to keeping HCV-positive patients on dialysis.
Indeed, it was demonstrated that the outcome of HCV-
positive renal allograft recipients was better than their
counterparts who had remained on long-term dialysis
(86). There have been conflicting observations on
whether HCV positivity had a negative impact on patient
survival after kidney transplantation (87,88). In addition
to death from liver disease, some authors have reported
a higher incidence of severe infections in HCV-positive
individuals (87). The apparent discrepancies could be
partly accounted for by the heterogeneous severity of
liver disease before transplantation and the different
immunosuppressive regimes. There is general agreement
that HCV infection per se should not be regarded as a
contraindication against kidney transplantation, but that
prospective kidney transplant recipients must be carefully
assessed with regard to the severity of liver disease,
preferably with the aid of liver biopsy. The role of
genotyping and monitoring the virus load after tran-
splantation in the clinical management of patients has
not been established. The latter theoretically may allow
earlier detection of disease exacerbation and thus
therapeutic intervention. Patients must be counseled
before transplantation about the subsequent risk of liver
complications, and the possible requirement for inter-
feron therapy, because the latter might have a detrimental
effect on the renal allograft.
Hepatitis C virus-related renal diseases
after kidney transplantation
Membranoproliferative glomerulonephritis, with or
without cryoglobulinemia, is the most common form of
HCV-related allograft disease, affecting up to 5% of
HCV-positive renal allograft recipients (89,90). As-
sociations between allograft membranous nephropathy
or thrombotic microangiopathy and HCV infection have
also been reported (91,92). The onset of clinical mani-
festations attributed to these complications can vary from
months to years after transplantation. Whether these
complications might respond to interferon therapy has
not been elucidated, but allograft survival could be
reduced by the immunological actions of interferon per
se.
MONITORING AND TREATMENT
In view of the increased propensity for liver com-
plications, HCV-positive patients should be monitored
with regard to their hepatitic activity, the development
of cirrhosis, and the development of hepatocellular
carcinoma. Regular measurement of the levels of liver
enzymes and alpha fetoprotein is mandatory. It is
noteworthy that the normal upper limits of liver enzymes
are lower in dialysis patients compared with non-dialyzed
individuals. The prothrombin time should be measured
when there is suspicion of liver disease that might result
in significant functional impairment, when surveillance
for other complications of portal hypertension is also
indicated. The levels of calcineurin inhibitors need to be
closely monitored in renal allograft recipients with
chronic active hepatitis, in view of their predominant
metabolism by the liver.
Interferon, pegylated interferon, and
ribavirin
About 5% to 15% of non-uremic patients with chronic
hepatitis C can achieve sustained virologic response to
interferon monotherapy given at 3 to 6 MU three times
weekly for 6 to 12 months, with concomitant im-
provement in liver abnormalities (93). The response rate
increases 30% to 40% after combination therapy with
ribavirin. Factors that affect the response rate include:
1. hepatitis C virus genotype–genotype 1 responds less
well to therapy compared with genotypes 2 or 3;
2. liver histology–the response rate may be lower in
patients with bridging fibrosis or cirrhosis;
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3. virus load–high baseline levels of HCV RNA have
been associated with lower response rates.
The attachment of polyethylene glycol to interferon
reduces its rate of absorption after subcutaneous
injection, reduces its renal and cellular clearance, and
decreases its immunogenicity, thereby resulting in
prolongation of its half-life. A controlled study with
pegylated interferon in non-uremic patients has
demonstrated better sustained response rates of up to
23%, compared with 12% in patients receiving standard
interferon-α therapy (94). Early results from ongoing
studies that examine combination therapy of pegylated
interferon with ribavirin have shown significantly
improved virologic response rates exceeding 50% (95).
In contrast to non-renal-failure patients, where interferon
therapy is well tolerated in the majority, dialysis patients
have a higher incidence of adverse effects, which include
malaise, reduced appetite, malnutrition, exacerbation of
anemia, and resistance to erythropoietin therapy, thereby
resulting in a high drop-out rate (96-98). Such differences
from non-uremic patients may be related to the reduced
clearance of interferon as well as the underlying uremic
state. Interferon therapy in HCV-positive renal allograft
recipients has been associated with a high incidence
(exceeding 46%) of renal allograft dysfunction or acute
graft failure, because of acute rejection or tubulo-
interstitial disease (99-102). These patients may also be
less likely to have a sustained response. Whether ribavirin
may have a role in the treatment of HCV-positive renal
transplant recipients has not been investigated, but it is
probably wise to avoid using ribavirin in dialysis patients,
because anemia will be exacerbated by drug-induced
hemolysis (103).
The optimal timing, the choice of therapeutic agents, the
duration of therapy, and above all, the decision on which
patients should be treated, are the critical issues
pertaining to the treatment of HCV infection in patients
on dialysis or after kidney transplantation. Many of these
issues have remained unresolved. Although there is
increasing promising data on the use of pegylated
interferon in the treatment of HCV infection in non-
uremic patients, and favorable results with the con-
comitant use of interferon and ribavirin have been
reported, these agents have substantial adverse effects
in patients on renal replacement therapy. Therefore, the
decision whether to start treatment has to be in-
dividualized, and the risks incurred by the therapeutic
agents need to be weighed against those from HCV-
induced liver complications. Notwithstanding, about
20% of HCV-positive dialysis patients can achieve
sustained clearance of HCV with interferon therapy (97).
It is reasonable to attempt treatment before trans-
plantation, because the administration of interferon in
renal allograft recipients is associated with a high risk
of renal allograft dysfunction, and should be reserved
for patients who demonstrate progressive and severe
HCV-related liver disease (99).
CONCLUSIONS
Much information on the virologic and clinical aspects
of HCV infection in patients on renal replacement the-
rapy has accumulated since the virus was cloned in 1989.
The long-term effects of HCV infection on clinical out-
come, especially in immunosuppressed renal allograft
recipients, remain to be elucidated. Treatment of HCV
infection in dialysis patients or renal allograft recipients
still presents a difficult clinical problem, because there
is as yet no effective and safe agent that is applicable to
these patients. The prevention of new HCV infections
by rigorously following measures that have proven
efficacy is therefore important.
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